Actively Recruiting
Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients
Led by University of Miami · Updated on 2026-03-23
100
Participants Needed
1
Research Sites
130 weeks
Total Duration
On this page
Sponsors
U
University of Miami
Lead Sponsor
E
Eurofins Viracor
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the clinical outcomes of Cytomegalovirus (CMV) virus in the participants' body. Therefore, the study team will follow the participants' immunological response based on the Cytomegalovirus (CMV) virus testing.
CONDITIONS
Official Title
Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients over 18 years of age
- Lung transplant candidates with positive CMV IgG
- Anticipated to receive a lung transplant (both double lung and single lung)
You will not qualify if you...
- Negative CMV IgG prior transplant
- Pregnant or breastfeeding women
- HIV infected patients
- Combined organ (e.g., lung-heart, lung-kidney) transplant candidates
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Miami
Miami, Florida, United States, 33136
Actively Recruiting
Research Team
Y
Yoichiro Natori, MD
CONTACT
L
Lissett Moni
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here